Keyword Analysis & Research: namuscla
Keyword Research: People who searched namuscla also searched
Search Results related to namuscla on Search Engine
-
Namuscla | European Medicines Agency
https://www.ema.europa.eu/en/medicines/human/EPAR/namuscla
WEBNamuscla is a medicine used to treat symptoms of myotonia (muscle stiffness) in patients with non-dystrophic myotonic disorders, a group of inherited muscle disorders. Non-dystrophic means no muscle wasting occurs in patients affected by the condition.
DA: 58 PA: 77 MOZ Rank: 29
-
Mexiletine - Wikipedia
https://en.wikipedia.org/wiki/Mexiletine
WEBMexiletine (sold under the brand names Mexitil and Namuscla) is a medication used to treat abnormal heart rhythms, chronic pain, and some causes of muscle stiffness. Common side effects include abdominal pain, chest discomfort, drowsiness, headache, and nausea.
DA: 82 PA: 14 MOZ Rank: 27
-
Lupin Receives Approval from U.S. FDA for Arformoterol Tartrate
https://www.lupin.com/lupin-signs-distribution-agreement-with-medis-for-orphan-drug-namuscla/
WEBFeb 9, 2022 · NaMuscla® is the first and only antimyotonic agent licensed to treat symptomatic myotonia in adults with non-dystrophic myotonic disorders in Europe 8. In randomized controlled trials, NaMuscla® (167 to 500 mg/day) has been shown to significantly reduce myotonia compared to placebo, reducing skeletal muscle …
DA: 16 PA: 77 MOZ Rank: 61
-
Namuscla 167 mg hard capsules - Summary of Product …
https://www.medicines.org.uk/emc/product/9838/smpc
WEBJan 28, 2019 · Namuscla is indicated for the symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic disorders.
DA: 64 PA: 29 MOZ Rank: 90
-
Namuscla (mexiletine) - European Medicines Agency
https://www.ema.europa.eu/en/documents/overview/namuscla-epar-medicine-overview_en.pdf
WEBWhat is Namuscla and what is it used for? Namuscla is a medicine used to treat symptoms of myotonia (muscle stiffness) in patients with non-dystrophic myotonic disorders, a group of inherited muscle disorders. Non-dystrophic means no muscle wasting occurs in patients affected by the condition.
DA: 31 PA: 83 MOZ Rank: 87
-
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
https://www.ema.europa.eu/en/documents/product-information/namuscla-epar-product-information_en.pdf
WEBNamuscla capsules are Swedish orange hard shell gelatin capsules (20 mm) filled with white powder. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Namuscla is indicated for the symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic disorders. 4.2 Posology and method of administration Posology
DA: 74 PA: 54 MOZ Rank: 91
-
Overview - Lupin Neurosciences
https://lupin-neurosciences.com/healthcare-professionals/portfolio/namuscla/overview/
WEBNaMuscla ® is an antimyotonic agent which is approved by the European Medicines Agency to treat symptomatic myotonia in adults with non-dystrophic myotonic disorders. In randomized controlled trials, NaMuscla ® (mexiletine 167 to 500 mg/day 1 ) has been shown to significantly reduce myotonia compared to placebo, restoring skeletal muscle ...
DA: 85 PA: 78 MOZ Rank: 32
-
Improving the understanding of how patients with non-dystrophic
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633892/
WEBDec 1, 2021 · BMC Neurol. 2021; 21: 467. Published online 2021 Dec 1. doi: 10.1186/s12883-021-02491-3. PMCID: PMC8633892. PMID: 34852780. Improving the understanding of how patients with non-dystrophic myotonia are selected for myotonia treatment with mexiletine (NaMuscla): outcomes of treatment impact using a European …
DA: 89 PA: 95 MOZ Rank: 66
-
Orphan Drug NaMuscla® Receives European Commission …
https://www.lupin.com/orphan-drug-namuscla-receives-european-commission-approval-for-the-treatment-of-myotonia/
WEBJan 8, 2019 · The approval makes NaMuscla®, which recently had its orphan drug designation ratified by the EMA’s Committee for Orphan Medicinal Products (COMP), the first treatment to be licensed throughout the EU for the symptomatic treatment of myotonia in adults with NDM disorders.
DA: 5 PA: 50 MOZ Rank: 18
-
Effectiveness and safety of mexiletine in patients at risk for
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681134/
WEBAug 29, 2022 · This could further limit mexiletine use in patients who could benefit. In addition, as per European regulation, the authorization of Namuscla as an orphan drug for the neurological indication non-dystrophic myotonia granted a 10-year market exclusivity and prohibits import of mexiletine for VT/VF.
DA: 15 PA: 71 MOZ Rank: 31
